ADVERTISEMENT
regeneron monoclonal antibody sars-cov-2 covid-19 pandemic coronavirus neutralization b.1.351 variant south africa REGN10987 casirivimab and REGN10933 imdevimab
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

drug development, immunology, disease & medicine, microbiology

COVID-19 Vaccine Developers Gain Enhanced Access to Supercomputers
Lisa Winter | Mar 27, 2020 | 2 min read
Federal agencies, academic institutions, and industrial partners are joining forces to combat COVID-19 using artificial intelligence.
ADVERTISEMENT